1 – 10 of 15
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI : The ProScreen Randomized Trial
(
- Contribution to journal › Article
- 2022
-
Mark
Liproca Depot : A New Antiandrogen Treatment for Active Surveillance Patients
(
- Contribution to journal › Article
- 2019
-
Mark
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy : An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
(
- Contribution to journal › Article
- 2017
-
Mark
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study
(
- Contribution to journal › Article
- 2016
-
Mark
Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
(
- Contribution to journal › Article
- 2014
-
Mark
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
(
- Contribution to journal › Article
- 2013
-
Mark
Intermittent Androgen-deprivation Therapy in Prostate Cancer: A Critical Review Focused on Phase 3 Trials
(
- Contribution to journal › Article
- 2012
-
Mark
The Effect of Baseline Testosterone on the Efficacy of Degarelix and Leuprolide: Further Insights From A 12-Month, Comparative, Phase III Study in Prostate Cancer Patients
(
- Contribution to journal › Article
-
Mark
Prostate-Cancer Mortality at 11 Years of Follow-up
(
- Contribution to journal › Article